Streamlining CAR T-Cell Care Coordination and Evolving Outpatient Management in Multiple Myeloma

This segment integrates two key aspects of delivering CAR T-cell therapy in multiple myeloma: efficient coordination between community practices and treatment centers, and the evolving logistics of outpatient care following recent FDA label updates. Dr. Kaur explains that timely, complete referral information is essential for rapid evaluation and includes prior treatment history, cytogenetics, comorbidities, recent laboratory data, performance status, and any urgent concerns such as rapid progression. Early communication allows centers to anticipate bridging needs, plan apheresis, and streamline insurance authorization. Dr. Raje discusses how the shortened post infusion monitoring requirement for idecabtagene vicleucel, now reduced to at least one week, will improve workflow by decreasing inpatient time and easing caregiver and housing burdens. This change expands outpatient feasibility, provided close follow up, toxicity monitoring, and multidisciplinary support are maintained. Together, these practice updates enhance patient access, reduce logistical barriers, and support safer, more efficient delivery of CAR T-cell therapy.